Medtronic collaborates with Harvard Business Review; Stentys touts stent data at TCT;

@FierceMedDev: ICYMI yesterday: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. Article | Follow @FierceMedDev

@VarunSaxena2: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. More | Follow @VarunSaxena2

@EmilyWFierce: Report: AstraZeneca funnels billions into Dutch tax-avoidance scheme. FiercePharma story | Follow @EmilyWFierce

> Medtronic ($MDT) is the exclusive sponsor of the new Harvard Business Review Insight Center, which will facilitate conversation around this year's topic: "Measuring Costs and Outcomes in Healthcare." More

> Stentys touted data in support of its sirolimus-eluting Self-Apposing stent at TCT, saying the the rate of well-apposed struts was 99.3%. More

Biotech News

@FierceBiotech: 5 experts, 1 voice: Biotech bubble? It's different this time. Editor's corner | Follow @FierceBiotech

@JohnCFierce: Analysts, experts write off Merck's huge anacetrapib PhIII. Report | Follow @JohnCFierce

@DamianFierce: Entirely baffled by 's business model. More | Follow @DamianFierce

> Zafgen shares continue to slide on market fears. Item

> Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash. Report

> FDA misses approval date for Collegium's pain drug. News

Pharma News

@FiercePharma: Japan's Astellas splashes out $300M for Immunomic's LAMP-vax platform. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI: Sanofi's Kansas City, MO plant back on the block as its August 2016 closing looms. Story | Follow @EricPFierce

@CarlyHFierce: J&J plots $10B buyback as plummeting hep C sales tarnish Q3. Article | Follow @CarlyHFierce

> Former Pfizer chemist and Zoloft co-developer Ken Koe dies at 90. News

> Novo Nordisk chief Sørensen tops world's-best CEO ranking. More

Drug Delivery News

> Study finds EpiPens can injure children, recommends improved technique and design. More

> Russian Academy: Combining drugs with ionic liquids can up the solubility, cut polymorphism. News

> Medicines Co. enters Japanese market, handing over license to transdermal pain patch. Story

> OptiNose bags $30M in VC financing as partner Otsuka barrels toward its second PDUFA date. Article

> 3M takes on blood-brain barrier with Impel Neuropharma nasal drug delivery alliance. Report

Pharma Manufacturing News

> Pests again figure into issues in FDA warning letter to Indian API maker. More

> Cipla's new U.S. plant received Form 483 just ahead of deal. News

> CPhI report predicts growth in outsourcing for sterile injectables. More

> Aurobindo to expand India API plant fourfold. Story

> Hong Kong's gray market draws mainland Chinese looking for lifesaving meds they can't afford at home. Article

Pharma Asia News

> HK-listed 3SBio inks oncology antibody drug deal with South Korea's Alteogen. Story

> CIMB says Malaysian pharmas have scope to adjust to TPP changes. Report

> China's Innovent Biologics deepens pact with Eli Lilly on immuno-oncology. Article

> Japan's Astellas splashes out $300M for Immunomic's LAMP-vax platform. Item

> Hong Kong drugstores attract Chinese customers for cancer, hep C drugs. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.